Document Detail


Valproic acid attenuates blood-brain barrier disruption in a rat model of transient focal cerebral ischemia: the roles of HDAC and MMP-9 inhibition.
MedLine Citation:
PMID:  20978517     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, is known to protect against cerebral ischemia. The effects of VPA on blood-brain barrier (BBB) disruption were investigated in rats subjected to transient middle cerebral artery occlusion (MCAO). Postischemic VPA treatment remarkably attenuated MCAO-induced BBB disruption and brain edema. Meanwhile, VPA significantly reduced MCAO-induced elevation of matrix metalloproteinase-9 (MMP-9), degradation of tight junction proteins, and nuclear translocation of nuclear factor-κB (NF-κB). Sodium butyrate, another HDAC inhibitor, mimicked these effects of VPA. Our findings suggest that BBB protection by VPA involves HDAC inhibition-mediated suppression of NF-κB activation, MMP-9 induction, and tight junction degradation.
Authors:
Zhifei Wang; Yan Leng; Li-Kai Tsai; Peter Leeds; De-Maw Chuang
Related Documents :
6801727 - Radiographic quantitation of reversible blood-brain barrier disruption in vivo.
8280117 - Blood-brain barrier transport of circulating alzheimer's amyloid beta.
19233517 - Polycyclic cage structures as carrier molecules for neuroprotective non-steroidal anti-...
6772797 - Starvation-induced changes in transport of ketone bodies across the blood-brain barrier.
7591797 - An evaluation of changes in composition and contamination of salvaged blood from the ca...
22098427 - High-throughput multiplex pcr genotyping for 35 red blood cell antigens in blood donors.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Intramural     Date:  2010-10-27
Journal Detail:
Title:  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism     Volume:  31     ISSN:  1559-7016     ISO Abbreviation:  J. Cereb. Blood Flow Metab.     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2011-01-04     Completed Date:  2011-02-03     Revised Date:  2012-01-02    
Medline Journal Info:
Nlm Unique ID:  8112566     Medline TA:  J Cereb Blood Flow Metab     Country:  United States    
Other Details:
Languages:  eng     Pagination:  52-7     Citation Subset:  IM    
Affiliation:
Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892-1363, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Blood-Brain Barrier / drug effects*
Blotting, Western
Body Water / metabolism
Brain Chemistry / drug effects,  physiology
Brain Edema / drug therapy,  etiology
Butyrates / pharmacology
Coloring Agents
Evans Blue
Histone Deacetylase Inhibitors / therapeutic use*
Histone Deacetylases / metabolism
Immunoglobulin G / metabolism
Infarction, Middle Cerebral Artery / drug therapy,  pathology
Ischemic Attack, Transient / drug therapy*,  pathology*
Male
Matrix Metalloproteinase 9 / antagonists & inhibitors*
NF-kappa B / biosynthesis,  genetics
Neuroprotective Agents*
Protease Inhibitors*
Rats
Rats, Sprague-Dawley
Tight Junctions / drug effects,  pathology
Valproic Acid / pharmacology*
Chemical
Reg. No./Substance:
0/Butyrates; 0/Coloring Agents; 0/Histone Deacetylase Inhibitors; 0/Immunoglobulin G; 0/NF-kappa B; 0/Neuroprotective Agents; 0/Protease Inhibitors; 314-13-6/Evans Blue; 99-66-1/Valproic Acid; EC 3.4.24.35/Matrix Metalloproteinase 9; EC 3.5.1.98/Histone Deacetylases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Spreading depression and related events are significant sources of neuronal Zn2+ release and accumul...
Next Document:  Leptin augments cerebral hemodynamic reserve after three-vessel occlusion: distinct effects on cereb...